Reported 2 days ago
Despite a 75% drop in share price over the past three years, investing in Moderna could present long-term opportunities. However, investors should prepare for declining revenues, as demand for COVID-19 vaccines has waned and new products may take years to generate growth. Moderna's recent $590 million government grant for influenza vaccine research signifies strong governmental support, indicating potential for future business, but immediate returns may be modest.
Source: YAHOO